# CoQ10: Ubiquinol vs Ubiquinone, What the Independent Evidence Shows

Independent research does not support the "ubiquinol is 2 to 3x more bioavailable" claim: López-Lluch 2019 and Mantle & Dybring 2020 both find that carrier lipid and formulation, not redox form, drive CoQ10 absorption, so a well-formulated ubiquinone softgel in oil can match or beat a poorly-formulated ubiquinol. The one positive heart-failure trial (Q-SYMBIO) used ubiquinone at 300 mg/day, and the studies behind the 2 to 3x line each have a disclosed financial link to the ubiquinol maker. Ubiquinol stays defensible for statin users, adults over 60, and fat-malabsorption cases, but that case is mechanistic, not head-to-head proven.

"Ubiquinol absorbs 2 to 3x better than ubiquinone." It is the supplement industry's most-repeated bioavailability line. But the studies behind it all share one feature worth flagging. Here is the honest read for 2026.

## On this page

- What Does CoQ10 Actually Do?
- Where Did the "2 to 3x More Bioavailable" Line Come From?
- What Does Independent Research Show?
- Where Might Ubiquinol Actually Help?
- What Does CoQ10 Have Real Clinical Evidence For?
- How Much CoQ10 Should You Take, and With What?
- What Should You Buy in DACH (2026)?
- Why Do EU Labels Make No Health Claims?
- So What Should You Actually Do?

## FAQ

- So should I take ubiquinol or ubiquinone?
- What dose actually works?
- Is the heart-failure benefit real?
- Does CoQ10 help with statin side effects?
- Can I take CoQ10 with warfarin?
- Why is ubiquinol so much more expensive?
- Does it actually help with energy or fatigue in healthy people?
- What's the difference between Kaneka ubiquinol and non-Kaneka ubiquinol?

## Sources

- Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP. (2014). The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2014.06.008
- Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. (2012). Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2012.04.156
- Alehagen U, Aaseth J, Alexander J, Johansson P. (2018). Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: a validation of previous 10-year follow-up. PLoS ONE. https://doi.org/10.1371/journal.pone.0193120
- López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, Cortés-Rodríguez AB, Navas P. (2019). Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. https://doi.org/10.1016/j.nut.2018.05.020
- Mantle D, Dybring A. (2020). Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism. Antioxidants. https://doi.org/10.3390/antiox9050386
- Fladerer JP, Grollitsch S. (2023). Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality. Current Cardiology Reports. https://doi.org/10.1007/s11886-023-01992-6
- Hosoe K, Kitano M, Kishida H, Kubo H, Fujii K, Kitahara M. (2007). Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2006.07.001
- Failla ML, Chitchumroonchokchai C, Aoki F. (2014). Increased Bioavailability of Ubiquinol Compared to That of Ubiquinone Is Due to More Efficient Micellarization during Digestion and Greater GSH-Dependent Uptake and Basolateral Secretion by Caco-2 Cells. Journal of Agricultural and Food Chemistry. https://doi.org/10.1021/jf5017829
- Mei X, Zhu B, Soni K, Kasaraneni K, Panchal N. (2026). A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70042
- Banach M, Serban C, Ursoniu S, et al.. (2015). Statin therapy and plasma coenzyme Q10 concentrations — a systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research. https://doi.org/10.1016/j.phrs.2015.07.008
- Banach M, Serban C, Sahebkar A, et al.. (2015). Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2014.08.021
- Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. (2018). Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association. https://doi.org/10.1161/JAHA.118.009835
- Taylor BA, Lorson L, White CM, Thompson PD. (2015). A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2014.12.016
- Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. https://doi.org/10.1212/01.WNL.0000151975.03598.ED
- Sazali S, Badrin S, Norhayati MN, Idris NS. (2021). Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine — a meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2020-039358
- Lafuente R, González-Comadrán M, Solà I, López G, Brassesco M, Carreras R, Checa MA. (2013). Coenzyme Q10 and male infertility: a meta-analysis. Journal of Assisted Reproduction and Genetics. https://doi.org/10.1007/s10815-013-0047-5
- Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, et al.. (2014). A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2014.131
- Ho MJ, Li EC, Wright JM. (2016). Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD007435.pub3
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). (2010). Scientific Opinion on the substantiation of health claims related to coenzyme Q10. EFSA Journal. https://doi.org/10.2903/j.efsa.2010.1793
- Kalén A, Appelkvist EL, Dallner G. (1989). Age-related changes in the lipid compositions of rat and human tissues. Lipids. https://doi.org/10.1007/BF02535072
- Spigset O. (1994). Reduced effect of warfarin caused by ubidecarenone. The Lancet. https://doi.org/10.1016/S0140-6736(94)90736-6
- Engelsen J, Nielsen JD, Winther K. (2002). Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thrombosis and Haemostasis
- Langsjoen PH, Langsjoen AM. (2014). Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.73
- Evans M, Baisley J, Barss S, Guthrie N. (2009). A randomized, double-blind trial on the bioavailability of two CoQ10 formulations. Journal of Functional Foods. https://doi.org/10.1016/j.jff.2008.09.010

_Full guide: https://longevity-switzerland.com/en/guide/coq10-ubiquinol_

---

_Canonical: https://longevity-switzerland.com/en/guide/coq10-ubiquinol · Part of Longevity Cities · Updated 2026-06-22_